Scientific Protein Laboratories Statement Regarding Heparin Recall In Japan

We have learned that, as a precaution, three Japanese companies have recalled heparin whose active pharmaceutical ingredient (API) was sourced in China and processed by SPL. The three Japanese companies made clear that the recall was simply a precaution, as there has not been a pattern of adverse reactions to heparin reported in Japan similar to what has been observed in the U.S. and Germany.